Phase I/II Dose-Finding, Safety, Tolerance, and Pharmacokinetics Study of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in HIV-Infected and TB Co-Infected Infants and Children
Latest Information Update: 22 Jul 2022
At a glance
- Drugs Raltegravir (Primary) ; Antiretrovirals; Rifampicin
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- 11 Mar 2020 Results from Cohort 3 (4 wks to <2 yrs) using RAL chewable tablets as a dispersible tablet presented at the 27th Conference on Retroviruses and Opportunistic Infections
- 11 Dec 2019 Status changed from active, no longer recruiting to completed.
- 15 Nov 2019 Results (n=26) in HIV-infected infants and children receiving ART and RIF-containing therapy for TBpublished in the AIDS